JPMorgan Chase set a €122.00 ($148.78) target price on Bayer (FRA:BAYN) in a research report released on Thursday morning. The firm currently has a buy rating on the healthcare company’s stock.
A number of other equities analysts also recently commented on BAYN. Barclays set a €95.00 ($115.85) target price on Bayer and gave the company a sell rating in a report on Monday, April 30th. Commerzbank set a €111.00 ($135.37) target price on Bayer and gave the company a buy rating in a report on Thursday. Baader Bank set a €140.00 ($170.73) target price on Bayer and gave the company a buy rating in a report on Thursday. Sanford C. Bernstein set a €123.00 ($150.00) target price on Bayer and gave the company a buy rating in a report on Thursday. Finally, Goldman Sachs set a €125.00 ($152.44) price objective on Bayer and gave the stock a buy rating in a report on Friday, April 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. Bayer presently has an average rating of Buy and an average target price of €117.68 ($143.51).
Shares of BAYN stock opened at €101.88 ($124.24) on Thursday. Bayer has a fifty-two week low of €91.58 ($111.68) and a fifty-two week high of €123.82 ($151.00).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.